IRIS
TOGNOLINI, Massimiliano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.690
AS - Asia 6.325
EU - Europa 6.111
SA - Sud America 904
AF - Africa 394
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 2
Totale 23.436
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.478
SG - Singapore 2.143
CN - Cina 1.833
IT - Italia 1.716
VN - Vietnam 1.093
FI - Finlandia 830
IE - Irlanda 753
SE - Svezia 729
BR - Brasile 719
DE - Germania 661
HK - Hong Kong 438
UA - Ucraina 329
FR - Francia 251
ZA - Sudafrica 250
GB - Regno Unito 199
NL - Olanda 185
TR - Turchia 183
IN - India 164
CA - Canada 119
RU - Federazione Russa 115
BD - Bangladesh 84
AR - Argentina 78
AT - Austria 64
BE - Belgio 64
CI - Costa d'Avorio 56
MX - Messico 53
JP - Giappone 49
ID - Indonesia 46
IQ - Iraq 45
KR - Corea 37
RO - Romania 36
CZ - Repubblica Ceca 35
PH - Filippine 34
EC - Ecuador 33
ES - Italia 31
TH - Thailandia 29
PK - Pakistan 27
PL - Polonia 24
JO - Giordania 19
VE - Venezuela 19
LT - Lituania 18
CM - Camerun 17
CO - Colombia 17
MA - Marocco 15
SA - Arabia Saudita 14
TN - Tunisia 13
EG - Egitto 12
CH - Svizzera 11
CL - Cile 11
UZ - Uzbekistan 11
MY - Malesia 10
EU - Europa 9
PA - Panama 9
AL - Albania 8
BO - Bolivia 8
KE - Kenya 8
NP - Nepal 8
PY - Paraguay 8
AZ - Azerbaigian 7
HU - Ungheria 7
JM - Giamaica 7
KG - Kirghizistan 7
TW - Taiwan 7
BG - Bulgaria 6
PE - Perù 6
AE - Emirati Arabi Uniti 5
CR - Costa Rica 5
DZ - Algeria 5
HN - Honduras 5
KZ - Kazakistan 5
SI - Slovenia 5
SN - Senegal 5
DO - Repubblica Dominicana 4
EE - Estonia 4
GR - Grecia 4
HR - Croazia 4
IR - Iran 4
PS - Palestinian Territory 4
RS - Serbia 4
SC - Seychelles 4
BH - Bahrain 3
BY - Bielorussia 3
DK - Danimarca 3
ET - Etiopia 3
NO - Norvegia 3
OM - Oman 3
PT - Portogallo 3
TT - Trinidad e Tobago 3
UY - Uruguay 3
AU - Australia 2
CY - Cipro 2
GA - Gabon 2
LB - Libano 2
LV - Lettonia 2
NG - Nigeria 2
QA - Qatar 2
SV - El Salvador 2
A1 - Anonimo 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
Totale 23.418
Salva come PNG Salva come JPEG
Città #
Dallas 2.969
Singapore 1.134
Ashburn 777
Dublin 745
Chandler 737
San Jose 559
Parma 524
Santa Clara 467
Ann Arbor 434
Beijing 424
Hong Kong 408
Jacksonville 359
Ho Chi Minh City 349
Dearborn 309
Boardman 251
Hanoi 250
Johannesburg 238
Munich 234
Nanjing 156
New York 154
Shanghai 152
Izmir 151
Los Angeles 150
Princeton 130
Hefei 128
Helsinki 127
Lauterbourg 124
Milan 119
Wilmington 110
Bremen 107
Bologna 86
San Mateo 79
São Paulo 71
Buffalo 62
Shenyang 59
Columbus 58
Toronto 58
Brussels 57
Kunming 57
Moscow 57
Abidjan 56
Vienna 52
Council Bluffs 49
Hebei 48
Jinan 48
Nanchang 47
Modena 45
Guangzhou 43
Turku 43
Frankfurt am Main 42
Haiphong 42
Seattle 41
Tokyo 41
Da Nang 40
Rome 38
Woodbridge 35
London 34
Chicago 33
Rio de Janeiro 33
Des Moines 32
Brescia 31
Bengaluru 30
Changsha 29
The Dalles 29
Tianjin 29
Jiaxing 28
Orem 28
Bangalore 27
Seoul 27
Brooklyn 24
Jakarta 24
Nuremberg 24
Fremont 23
Hangzhou 23
Reggio Emilia 23
Lubbock 21
Montreal 21
Belo Horizonte 20
Boston 20
Düsseldorf 20
Houston 20
Stockholm 20
Ottawa 19
Piacenza 19
Brno 18
Mexico City 18
Phoenix 18
Grafing 17
Turin 17
Amman 16
Pune 16
Amsterdam 15
Atlanta 15
Biên Hòa 15
Brasília 15
Chennai 15
Denver 15
Poplar 15
Warsaw 15
Bangkok 14
Totale 15.095
Salva come PNG Salva come JPEG
Nome #
1,8-Naphthyridines IX. Potent anti-inflammatory and/or analgesic activity of a new group of substituted 5 amino[1,2,4]triazolo[4,3-a] [1,8]naphthyridine-6 carboxamides, of some their Mannich base derivatives and of one novel substituted 5-amino-10-oxo-10Hpyrimido[1,2-a [1,8]naphthyridine-6-carboxamide derivative 1.683
1,5-Benzodiazepines Part XIII. Substututed 4H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-5-amines and 4H-imidazo-[1,2-a][ 1,5]benzodiazepin-5-amines as analgesic, anti-inflammatory and/or antipyretic agents with low acute toxicity 1.672
Principi di farmacognosia e fitoterapia. Seconda edizione 698
A Pharmacological Investigation of Eph-Ephrin Antagonism in Prostate Cancer: UniPR1331 Efficacy Evidence 298
Principi di farmacognosia e fitoterapia 258
1,8-Naphthyridines V. Novel N-substituted 5-amino-N,N-diethyl-9-isopropyl [1,2,4]triazolo[4,3-a] [1,8]naphthyridine-6-carboxamides, as potent anti-inflammatory and/or analgesic agents completely devoid of acute gastrolesivity 250
Targeting the Eph/ephrin system as anti-inflammatory strategy in IBD 250
Excipient-free pulmonary insulin dry powder: Pharmacokinetic and pharmacodynamics profiles in rats 244
Pharmacological characterization of second generation FXR agonists as effective EphA2 antagonists: A successful application of target hopping approach 240
Inhibition of Eph/ephrin interaction with the small molecule UniPR500 improves glucose tolerance in healthy and insulin-resistant mice 239
Discovery of a new 1-(phenylsulfonyl)-1H-indole derivative targeting the EphA2 receptor with antiproliferative activity on U251 glioblastoma cell line 232
Drug-gut microbiota metabolic interactions: the case of UniPR1331, selective antagonist of the Eph-ephrin system, in mice 215
Optimization of EphA2 antagonists based on a lithocholic acid core led to the identification of UniPR505, a new 3α-carbamoyloxy derivative with antiangiogenetic properties 214
Antiplatelet and antithrombotic activities of essential oil from wild Ocotea quixos (Lam.) Kosterm. (Lauraceae) calices from Amazonian Ecuador 210
Development of an orally bioavailable small molecule targeting Eph-ephrin system: in vitro and in vivo anticancer activity. 202
Pharmacological evaluation of new bioavailable small molecules targeting Eph/ephrin interaction 201
Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. 200
UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. 197
Combining ligand- and structure-based approaches for the discovery of new inhibitors of the EPHA2-ephrin-A1 interaction 196
Analgesic properties of benzisothiazole/ benzimidazole derivatives with acidic groups 196
Discovery and development of Eph-ephrin antagonists endowed with antiangiogenic properties 191
Polyphenol rich botanicals used as food supplements interfere with EphA2-ephrinA1 system. 190
1,8-Naphthyridines VII. New substituted 5-amino[1,2,4]triazolo[4,3-a][1,8]naphthyridine-6-carboxamides and their isosteric analogues, exhibiting notable anti-inflammatory and/or analgesic activities, but no acute gastrolesivity. 190
1,8-Naphthyridines VIII. Novel 5-aminoimidazo[1,2-a] [1,8]naphthyridine-6-carboxamide and 5-amino[1,2,4]triazolo[4,3-a] [1,8]naphthyridine-6-carboxamide derivatives showing potent analgesic or anti-inflammatory activity, respectively, and completely devoid of acute gastrolesivity. 189
2,4-Substituted benzopyrano[4,3-d]pyrimidines and benzopyrano[4,3-d]pyrimidin-5-ones: synthesis and antiplatelet activity 188
Accommodation and peristalsis are functional responses to chronic obstruction in rat hypertrophic ileum 187
2-Amino-1,2-benzisothiazolin-3-one derivatives as powerful antiplatelet agents 183
Design and structure-activity relationship of amino acid derivatives of lithocholic acid as novel EphA2 antagonists 182
NEW EPH ANTAGONISTS DISCRIMINATING BETWEEN EPH-AS AND EPH-BS CLASSES 176
Enhanced photosensitizing properties of protein bound curcumin 176
Suppression of inflammatory events associated to intestinal ischemia-reperfusion by 5-HT1A blockade in mice 176
Structure–Activity Relationships and Mechanism of Action of Eph–ephrin Antagonists: Interaction of Cholanic Acid with the EphA2 Receptor 176
Cognition enhancing effect in rats of a selected histamine H3 receptor antagonist with good brain penetration 174
A simple GC-MS method for the screening of betulinic, corosolic, maslinic, oleanolic and ursolic acid contents in commercial botanicals used as food supplement ingredients 173
Metabolic Soft Spot and Pharmacokinetics: Functionalization of C-3 Position of an Eph–Ephrin Antagonist Featuring a Bile Acid Core as an Effective Strategy to Obtain Oral Bioavailability in Mice 172
Lithocholic acid is an Eph-ephrin ligand interfering with Eph-kinase activation 171
inibitori eph-ephrin biodisponibili oralmente 170
Hypericin - apomyoglobin an enhanced photosensitizer complex for the treatment of tumor cells 170
270 Discovery, development and optimization of low molecular weight EPH–ephrin protein–protein inhibitors 166
A photosensitizing fusion protein with targeting capabilities 166
1-Methyl and 1-(2-hydroxyalkyl)-5-(3-alkyl/cycloalkyl/phenyl/naphthylureido)-1H-pyrazole-4-carboxylic acid ethyl esters as potent human neutrophil chemotaxis inhibitors 163
Development of 3-oxo-cholenic derivatives as Eph antagonists able to block in vitro angiogenesis 162
Perturbation of The EphA2-EphrinA1 System in Human Prostate Cancer Cells by Colonic (Poly)phenol Catabolites 161
Discovery and development of small molecules targeting Eph-ephrin system in glioblastoma: an academic history 161
UniPR1331: small Eph/ephrin antagonist beneficial in intestinal inflammation by interfering with type-B signaling 161
2-Amino-1,2-benzisothiazolin-3-one Derivatives: Synthesis and Assessment of their Antiplatelet/Spasmolytic Effects 160
Multiple approaches for the discovery and development of small molecules targeting Eph-ephrin protein-protein interaction 160
Botanicals used as food supplements interfering with EphA2-ephrinA1 system: a screening study 157
Eph/ephrin targeting with a small molecule improves glucose tolerance in healthy and insulin-resistant mice 156
Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis 155
Protein-Protein Interaction Inhibitors Targeting the Eph-Ephrin System with a Focus on Amino Acid Conjugates of Bile Acids 153
5-Alkoxy-2-hydrazino and 5-methoxy-2-amino-5H[1]benzopyrano[4,3-d]pyrimidines: synthesis and pharmacological activity 152
Intestinal Hypoxia and reperfusion: role for Eph-ephrin system 152
Structure activity relationship of new EphA2 ligands 150
Evaluation of the anti-tumor activity of small molecules targeting eph/ephrins in apcmin j mice 150
Molecular Determinants of EphA2 and EphB2 Antagonism Enable the Design of Ligands with Improved Selectivity 149
Influence of adenosine in the systemic and local injury caused by mesenteric ischemia-reperfusion in mice 149
Design and structure-activity relationships of amino acid derivatives of lithocholic acid as novel EphA2 receptor antagonists. 148
Analysis of adam12-mediated ephrin-a1 cleavage and its biological functions 148
Δ5-Cholenoyl-amino acids as selective and orally available antagonists of the Eph-ephrin system 148
Exploiting Free-Energy Minima to Design Novel EphA2 Protein-Protein Antagonists: From Simulation to Experiment and Return 146
Preventive effect of 5-HT1A receptor agonist Buspirone on mesenteric ischemia/reperfusion-induced inflammatory injuries in mice 146
PHARMACOLOGICAL CHARACTERIZATION OF NEW COMPOUNDS AIMED AT INHIBITING EPH-EPHRIN INTERACTION IN GLIOBLASTOMA 145
Comparative Analysis of Virtual Screening Approaches in the Search for Novel EphA2 Receptor Antagonists 145
Discovery and development of low molecular weight Eph-ephrin protein-protein inhbi-tors endowed with antiangiogenic activity 144
High-Density Lipoproteins at the Interface between the NLRP3 Inflammasome and Myocardial Infarction 142
Discovery of natural extracts interfering with EphA2-ephrinA1 system 142
Combining pharmacology, target hopping and computational medicinal chemistry to discover novel scaffold targeting EPH-ephrin interaction. 142
The ellagitannin colonic metabolite urolithin D selectively inhibits EphA2 phosphorylation in prostate cancer cells 140
UniPR1331, a small molecule targeting Eph/ephrin interaction, prolongs survival in glioblastoma and potentiates the effect of antiangiogenic therapy in mice 139
2-Amino/azido/hydrazino-5-alkoxy-5H-[1]benzopyrano[4,3-d]pyrimidines: synthesis and pharmacological evaluation 138
Metadynamics for perspective drug design: Computationally driven synthesis of new protein-protein interaction inhibitors targeting the EphA2 receptor 138
Computer-Aided Design of Novel Antagonists of the EphA2 Receptor 135
Ephrin receptor type-A2 (EphA2) targeting in cancer: a patent review (2018-present) 134
Target Hopping as a Useful Tool for the Identification of Novel EphA2 Protein–Protein Antagonists 133
RESPONSIVENESS OF LONGITUDINAL AND CIRCULAR MUSCLE TO RELAXING MEDIATORS IS DIFFERENTIALLY AFFECTED IN RAT HYPERTROPHIED ILEUM 132
Disruption of Eph-ephrin B signaling pathways mitigates inflammation in a murine model of Crohn’s disease 132
Comparative screening of plant essential oils: phenylpropanoid moiety as basic core for antiplatelet activity 132
Cholenic acid derivative UniPR1331 impairs tumor angiogenesis via blockade of VEGF/VEGFR2 in addition to Eph/ephrin 132
Eph-ephrin antagonism in tumor angiogenesis and growth: UniPR1331 preclinical evidence. 132
Evidence for the involvement of 5-HT(2A) receptors in mild mesenteric ischemia/reperfusion dysfunctions in mice 131
Pharmacological screening of novel antiplatelet agents with analgesic activity 129
Mesenteric ischemia-reperfusion: an overview of preclinical drug strategies 128
Protection by the EPH-EPHRIN System Against Mesenteric Ischemia-Reperfusion Injury 128
Novel antiplatelet and antithrombotic activities of essential oil from Lavandula hybrida Reverchon "Grosso" 127
Are we using the right pharmacological tools to target EphA4? 127
Progress in 5H [1] benzopyrano[4,3-d]pyrimidin-5-amine series: “-methoxy derivatives effective as antiìplatelet agents with analgesic activity 124
Antinflammatory properties of novel 5-amino[1,2,4]-triazolo[4,3-a][1,8]naphthyridines-caroboxamides derivatives 124
Lithocholic acid competitively inhibitis EphA2-ephrinA1 binding: pharmacological and structural considerations. 124
PHENYLPROPANOID RICH ESSENTIAL OILS AS POTENTIAL ANTITHROMBOTICS ENDOWED WITH GASTROPROTECTIVE EFFECTS 122
New insights into the pharmacological properties of potent antiplatelet 2-amino-benzo|d|isothiazol-3-one derivatives 122
Target-hopping: a useful approach to identify novel Eph receptor antagonists 122
Lithocholic acid competitively inhibits EphA2-ephrinA1 binding: pharmacological and structural considerations. 121
5-substituted derivatives of 6-amino-1,3-diphenyl-2-thioxo-2.3-dihydropyrimidin-4(1H9-one as a new class of potent inhibitors of interleukin 8-induced chemotaxis 121
6-amino-4-oxo-1,3-diphenyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carbonyl derivatives as a new class of potent inhibitors of Interleukin-8-induced neutrophil chemotaxis. 120
Synthesis and Structure-Activity Relationships of Amino Acid Conjugates of Cholanic Acid as Antagonists of the EphA2 Receptor. 118
Effects of subacute treatment with benzopyranopyrimidines in hemostasis and experimental thrombosis in mice 118
Inhibitors of blood platelet aggregation: synthesis and in vitro characterization of 2-amino-1,2-benzisothiazolin-3-one derivatives 116
Synthesis and Biological Evaluation of N-Pyrazolyl-N'-alkyl/benzyl/phenylureas: a New Class of Potent Inhibitors of Interleukin 8-Induced Neutrophil Chemotaxis 116
Investigation on the anti-inflammatory properties of Ocotea quixos Lam. essential oil. 115
Totale 19.778
Salva come PNG Salva come JPEG
Categoria #
all - tutte 67.615
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 67.615
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021224 0 0 0 0 0 0 0 0 0 62 118 44
2021/2022844 35 31 32 100 41 35 81 87 59 74 57 212
2022/20232.958 330 302 157 237 320 333 64 162 876 43 96 38
2023/20241.195 68 75 32 45 91 229 117 82 60 111 118 167
2024/20254.051 127 197 275 214 398 429 232 242 539 373 360 665
2025/20269.969 730 1.326 2.863 736 1.003 467 869 276 1.107 592 0 0
Totale 23.668